{"id":72927,"date":"2026-07-12T01:49:50","date_gmt":"2026-07-12T01:49:50","guid":{"rendered":"https:\/\/trialcontact.com\/?p=72927"},"modified":"2026-07-12T01:51:40","modified_gmt":"2026-07-12T01:51:40","slug":"advanced-esophageal-squamous-cell-carcinoma-combining-adebrelimab-immunotherapy-and-total-neoadjuvant-therapy","status":"publish","type":"post","link":"https:\/\/trialcontact.com\/?p=72927","title":{"rendered":"Advanced Esophageal Squamous Cell Carcinoma: Combining Adebrelimab Immunotherapy and Total Neoadjuvant Therapy"},"content":{"rendered":"<a href=\"https:\/\/trialcontact.com\/?add-to-cart=37694\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If you or someone you love has faced an esophageal cancer diagnosis, you know how overwhelming the news can be. Esophageal cancer ranks among the world\u2019s most deadly digestive malignancies, carrying steep rates of new diagnoses and fatalities every single year\u2014and the burden falls disproportionately on patients living in China. According to World Health Organization data from 2020, China recorded 324,000 new esophageal cancer cases and 301,000 deaths, accounting for over half of all global esophageal cancer incidence and mortality (53.70% and 55.35%, respectively). The most common form of this disease in East Asia is esophageal squamous cell carcinoma, or ESCC, a tough cancer that grows in the thin, flat lining of the food pipe.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For patients diagnosed with locally advanced resectable ESCC\u2014meaning the tumor has grown beyond the inner esophageal wall and may spread to nearby lymph nodes but has not traveled to distant organs\u2014surgery remains the gold standard curative treatment. For decades, doctors have paired surgery with pre-operative chemotherapy and radiation (called neoadjuvant chemoradiotherapy, or CRT) to shrink tumors, kill hidden tiny cancer deposits, and make complete surgical removal possible. Yet a critical gap persists: even after standard neoadjuvant chemoradiotherapy followed by surgery, between 36% and 50% of patients will see their cancer return or spread elsewhere in the body. Early recurrence brings very poor long-term survival odds, leaving millions of families searching for better, more effective treatment options.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This article breaks down a promising new clinical trial led by Dr. Yin Li and his team at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, a top national cancer center in Beijing. This trial tests a cutting-edge treatment strategy known as total neoadjuvant therapy (TNT) paired with adebrelimab, a homegrown Chinese immunotherapy drug. We will explain esophageal squamous cell carcinoma in plain language, walk through why standard treatment falls short for so many patients, unpack how immunotherapy and total neoadjuvant therapy work together, simplify the trial\u2019s core design without dense medical jargon, and outline what this research could mean for future esophageal cancer patients worldwide. Written for general readers\u2014patients, caregivers, and anyone curious about cancer research\u2014this piece avoids overly technical vocabulary and centers on hope, progress, and the real human impact of better cancer treatments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">What Is Locally Advanced Resectable Esophageal Squamous Cell Carcinoma?<br>Before diving into the trial itself, we first need to understand the disease it aims to treat: locally advanced resectable ESCC. Let\u2019s break every term down simply.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Your esophagus is the long, muscular tube connecting your throat to your stomach, responsible for moving food and liquid down into your digestive tract. Its inner lining is made of thin, flat \u201csquamous\u201d cells\u2014these are the cells where squamous cell carcinoma develops. Unlike esophageal adenocarcinoma (the more common esophageal cancer in Western nations, linked to acid reflux and obesity), ESCC is driven by long-term risk factors including hot food and beverage consumption, tobacco use, heavy alcohol intake, poor diet lacking fresh fruits and vegetables, and chronic esophageal irritation. It hits middle-aged and older adults hardest, with most diagnoses appearing in patients over 50 years old.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cLocally Advanced\u201d<br>\u201cLocally advanced\u201d means the tumor is no longer confined only to the surface lining of the esophagus. It has grown deeper into the esophageal muscle layers, and may have spread to nearby small lymph nodes in the chest. Crucially, the cancer has not metastasized (spread) to distant organs like the liver, lungs, or bones\u2014this is the line separating curable disease from widespread, incurable late-stage cancer. Doctors stage ESCC using the AJCC 8th Edition cancer staging system, and patients eligible for this trial fall into categories T1b\u20133N1\u20132M0 or T3N0M0: tumors that have invaded deeper tissue layers, with or without limited nearby lymph node involvement, and zero distant spread.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cResectable\u201d<br>Resectable means surgical teams can fully cut out every trace of visible tumor during an operation, achieving what surgeons call an R0 resection\u2014no cancer cells left along the cut edges of removed tissue. If a tumor invades major blood vessels, the windpipe, or other vital organs, it becomes unresectable, and surgery is no longer a viable cure option. This trial only enrolls patients whose scans confirm their tumors can be fully removed with an operation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Why This Cancer Is So Hard to Beat<br>Even with successful surgery after standard pre-op chemoradiotherapy, nearly half of patients face recurrence. Here are the two biggest barriers to lasting recovery:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Hidden microscopic cancer cells: Chemotherapy and radiation kill most large tumor masses, but tiny, invisible cancer cells can linger in lymph nodes or esophageal tissue. These leftover cells multiply over months or years, triggering recurrence or distant metastasis.<\/li>\n\n\n\n<li>Poor completion of post-surgery treatment: After surgery, many patients are prescribed adjuvant (post-operative) chemotherapy to wipe out leftover cancer cells. Unfortunately, fewer than half of eligible patients finish their full adjuvant treatment course. Surgical complications, fatigue, loss of appetite, pain, and logistical barriers lead to skipped or delayed doses, weakening the treatment\u2019s ability to stop cancer from coming back.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">A landmark study using nivolumab (another immunotherapy drug) offered a glimpse of a better path: among ESCC patients who had neoadjuvant chemoradiotherapy and surgery, those who received adjuvant immunotherapy lived significantly longer without cancer returning compared to patients who took a placebo. This proved immunotherapy could strengthen post-surgery protection\u2014but researchers wondered: what if we move immunotherapy earlier, before surgery, as part of a complete pre-operative treatment plan? That question birthed the total neoadjuvant therapy concept tested in this trial.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total Neoadjuvant Therapy (TNT): The Next Evolution of Pre-Surgery Cancer Care<br>To grasp why this trial matters, we first clarify the difference between standard neoadjuvant chemoradiotherapy (CRT) and total neoadjuvant therapy (TNT).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Standard Neoadjuvant Chemoradiotherapy (CRT)<br>The current global standard for locally advanced resectable ESCC follows a straightforward sequence:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Patients receive concurrent chemotherapy plus radiation therapy (CRT) before surgery. Radiation targets the local esophageal tumor, while chemo circulates through the body to attack any nearby hidden cancer cells.<\/li>\n\n\n\n<li>After finishing CRT, patients rest for 4\u20138 weeks to recover, then undergo esophageal resection surgery.<\/li>\n\n\n\n<li>If leftover cancer cells are found in the removed tissue after surgery (meaning they did not achieve a pathological complete response, or pCR), patients get months of post-surgery adjuvant chemo.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">The flaw in this model? All systemic anti-cancer drug treatment is split into two chunks: a small portion before surgery, and the rest after surgery. Surgery takes a massive toll on patients\u2019 bodies, making post-op treatment hard to tolerate and complete.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Total Neoadjuvant Therapy (TNT)<br>Total neoadjuvant therapy flips this script. Every single dose of systemic treatment\u2014chemotherapy and immunotherapy\u2014is delivered entirely before surgery, paired with radiation in a carefully timed sequence. There is no split of drug therapy before and after the operation. By completing all systemic anti-cancer treatment while patients are still in better pre-surgery physical condition, doctors hope to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Eliminate more hidden microscopic cancer cells all over the body before surgeons cut out the main tumor;<\/li>\n\n\n\n<li>Avoid the physical and logistical barriers that stop patients from finishing post-surgery adjuvant drugs;<\/li>\n\n\n\n<li>Dramatically raise the rate of pathological complete response (pCR)\u2014the golden standard of successful pre-op treatment, meaning zero cancer cells remain in the primary tumor or lymph nodes after therapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Early small-scale prospective studies worldwide confirm that pairing immunotherapy with TNT boosts pCR rates for ESCC, delivering powerful short-term tumor shrinkage with manageable side effects. But critical unanswered questions remain: What is the best order to give immunotherapy, chemo, and radiation before surgery? Does TNT plus immunotherapy beat standard CRT alone for long-term survival? This trial was designed to answer both questions in two distinct research phases: Phase 2 (exploratory) and Phase 3 (definitive, large-scale validation).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Meet Adebrelimab: The Immunotherapy Powering This Trial\u2019s New Treatment Regimens<br>Immunotherapy has revolutionized care for advanced esophageal cancer over the past decade, and adebrelimab stands as one of China\u2019s most important homegrown immune checkpoint inhibitors. Let\u2019s explain how it works without confusing medical jargon.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">How Cancer Hides From Your Immune System<br>Your body\u2019s immune system uses specialized white blood cells called T cells to hunt down and destroy abnormal, cancerous cells. Cancer cells evolved a clever trick to escape detection: they grow a protein called PD-L1 on their outer surface. When PD-L1 touches a matching protein (PD-1) on T cells, it sends a \u201cstop attacking\u201d signal that shuts the T cell\u2019s anti-cancer function down. The tumor effectively hits an invisibility switch, letting it grow unchecked.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Adebrelimab\u2019s Simple Mission<br>Adebrelimab is a lab-made monoclonal antibody\u2014a custom-built protein that locks onto PD-L1 on cancer cells. Once bound, it blocks PD-L1 from connecting with T cell PD-1, ripping away the tumor\u2019s invisibility cloak. Your dormant T cells wake back up, locate the cancer cells, and launch a targeted attack to kill them. Unlike chemotherapy, which poisons all fast-dividing cells (healthy and cancerous alike), immunotherapy harnesses your own natural immune defenses to target only malignant tissue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This drug is fully humanized, meaning it is engineered to match human immune proteins closely, lowering the risk of severe allergic reactions compared to older generations of antibody treatments. It has already earned official regulatory approval in China as first-line therapy for extensive-stage small cell lung cancer, with clinical data proving it extends overall survival and doubles long-term survival rates when combined with chemotherapy. Now, researchers are expanding its use into esophageal cancer perioperative (pre-surgery) care via this landmark trial.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Breaking Down the Clinical Trial: Goals, Structure, and Treatment Groups<br>This interventional randomized trial launched in March 2025 at the National Cancer Center in Beijing, led by principal investigator Dr. Yin Li, Head of the Esophageal and Mediastinal Surgery Department. It combines a Phase 2 exploratory stage and a Phase 3 confirmatory stage, with an estimated total enrollment of 474 patients, and projected study completion in May 2031. The core two-part design solves two separate research problems:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Phase 2: Test two different sequences of TNT + adebrelimab to find which order delivers better tumor shrinkage and safety profiles.<\/li>\n\n\n\n<li>Phase 3: Take the superior TNT regimen identified in Phase 2, then compare it head-to-head against the standard-of-care neoadjuvant CRT to prove it improves long-term survival for patients.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">No participants or doctors will be blinded to treatment assignments (open-label trial), meaning everyone knows which therapy each patient receives\u2014this simplifies monitoring for side effects and adjusting care plans as needed. Below is a plain-language overview of each treatment arm, avoiding complex dosage math while capturing the core sequence logic.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Phase 2: Two Experimental TNT Immunotherapy Sequences<br>Both Phase 2 groups receive the exact same three treatment tools\u2014adebrelimab immunotherapy, paclitaxel\/nab-paclitaxel + cisplatin chemotherapy, and 41.4Gy radiation split across 23 daily sessions\u2014only the order changes, creating two distinct treatment pathways:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>TNT Group One (Immuno-Chemo First, Then Radiation)<br>Patients start with two cycles of adebrelimab plus dual chemo (paclitaxel or albumin-bound nab-paclitaxel with cisplatin). After finishing these two pre-radiation cycles, they receive concurrent chemoradiotherapy (the same chemo drugs plus full radiation course). Once all TNT treatment wraps up, patients rest 4\u20138 weeks to recover before surgical resection of the esophagus.<br>The core idea here: hit microscopic circulating cancer cells first with immunotherapy and chemo to shrink distant hidden deposits, then use radiation to eliminate the main esophageal tumor mass.<\/li>\n\n\n\n<li>TNT Group Two (Radiation First, Then Immuno-Chemo)<br>This sequence reverses the order. Patients first complete the full concurrent chemoradiotherapy course (chemo + radiation targeting the primary tumor). Next, they receive two cycles of adebrelimab plus dual chemo to clear any leftover cancer cells that survived radiation. After recovery, patients undergo surgery.<br>The core logic here: shrink the large local tumor with radiation upfront, then deploy immunotherapy and chemo to mop up any residual cancer before surgery.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Phase 2\u2019s primary measuring stick is pCR rate\u2014how many patients have zero cancer left in their tumor and lymph nodes after all pre-op treatment. Researchers will also track secondary metrics including complete surgical removal (R0 resection rate), major pathological response (MPR, less than 10% tumor left), tumor regression grades, and short-term safety. Whichever group delivers higher pCR rates with tolerable side effects moves forward into the large Phase 3 trial as the official experimental TNT regimen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Phase 3: Head-to-Head Comparison of Superior TNT vs. Standard CRT<br>Once the better TNT sequence is selected from Phase 2, the trial shifts to its definitive randomized Phase 3 stage, splitting participants into two arms to compare the new treatment against global standard care:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Experimental TNT Treatment Group<br>Patients receive the winning Phase 2 TNT + adebrelimab regimen in full before surgery. After recovering from esophageal resection, they continue maintenance adebrelimab immunotherapy once every three weeks for a full year to guard against recurrence long-term.<\/li>\n\n\n\n<li>Control CRT Treatment Group (Standard Care)<br>This group receives the worldwide standard neoadjuvant chemoradiotherapy (chemo + radiation only, no pre-op immunotherapy) before surgery. After resection, patients split into two paths based on post-surgery pathology results:<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li>If they achieved pCR (no cancer remaining after CRT): No further treatment, routine observation only.<\/li>\n\n\n\n<li>If residual cancer is found (no pCR): One year of adjuvant adebrelimab immunotherapy after surgery, matching the maintenance window given to the experimental arm. Who Can Join This Trial?<br>Not every esophageal cancer patient qualifies for enrollment, and strict entry rules ensure consistent, reliable research data while protecting participant safety. Below is a streamlined breakdown of core inclusion (qualifying) and exclusion (disqualifying) criteria, written without medical shorthand. Core Rules to Participate (Inclusion Criteria)<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Willingly sign official informed consent paperwork to take part in research.<\/li>\n\n\n\n<li>Confirmed esophageal squamous cell carcinoma via biopsy tissue testing.<\/li>\n\n\n\n<li>CT, MRI, or endoscopic ultrasound scans prove thoracic esophageal cancer staged T1b\u20133N1\u20132M0 or T3N0M0 (locally advanced, resectable, no distant organ spread).<\/li>\n\n\n\n<li>Medical teams confirm surgery can fully remove all visible cancer (R0 resection achievable).<\/li>\n\n\n\n<li>Age 18 years or older, any gender eligible.<\/li>\n\n\n\n<li>Good overall physical function (ECOG performance status 0 or 1: able to complete daily self-care, no bed rest required).<\/li>\n\n\n\n<li>No prior anti-cancer drugs, radiation, or surgery for esophageal cancer before trial enrollment.<\/li>\n\n\n\n<li>Plan to complete all pre-op treatment followed by scheduled esophageal surgery.<\/li>\n\n\n\n<li>No medical conditions making surgery too dangerous (no surgical contraindications).<\/li>\n\n\n\n<li>Healthy major organ function: normal blood cell counts, liver and kidney function within safe limits, standard blood clotting ability.<\/li>\n\n\n\n<li>Patients who can become pregnant or partners of fertile participants must use reliable birth control during all treatment and follow-up periods.<\/li>\n\n\n\n<li>Able to attend all required hospital visits and comply with multi-year follow-up appointments. Why This Trial Matters for Esophageal Cancer Patients Worldwide<br>For patients, families, and global oncology researchers, fills three massive gaps in current esophageal cancer treatment knowledge:<\/li>\n\n\n\n<li>It Answers the Unresolved Question of Optimal TNT Immunotherapy Sequencing<br>Until now, no large prospective studies have directly compared the two core orders of immunotherapy, chemo, and radiation within a total neoadjuvant therapy framework for ESCC. Doctors lack clear guidance on whether to give immunotherapy before or after radiation during pre-op care. This Phase 2 head-to-head comparison will generate definitive, patient-centered data to set future global treatment guidelines.<\/li>\n\n\n\n<li>It Tests Whether TNT + Immunotherapy Beats Standard Chemoradiotherapy Long-Term<br>Standard CRT leaves nearly half of patients facing recurrence. If the Phase 3 results confirm the TNT immunotherapy regimen delivers higher pCR rates, longer event-free survival, and extended overall survival, this treatment pathway could become the new global standard for locally advanced resectable ESCC. Instead of splitting systemic therapy between pre and post-surgery, doctors will shift to fully pre-operative TNT plus immunotherapy, eliminating the barrier of incomplete post-op adjuvant treatment.<\/li>\n\n\n\n<li>It Validates a Domestic Chinese Immunotherapy for Curative Perioperative Esophageal Cancer Care<br>Adebrelimab represents a landmark achievement in China\u2019s independent biotech research\u2014this trial expands its approved use beyond late-stage lung cancer into potentially curable esophageal cancer treatment. If positive, it will create an affordable, locally manufactured immunotherapy option for millions of Asian ESCC patients, who bear the vast majority of global esophageal cancer burden, reducing reliance on expensive imported immune checkpoint drugs. Real-World Patient Impact<br>Imagine a 62-year-old patient diagnosed with locally advanced ESCC, whose doctor previously only offered standard chemoradiotherapy followed by surgery, with a nearly 50% chance the cancer would return within a few years. If this trial\u2019s treatment succeeds, that same patient will receive a full course of immunotherapy, chemo, and radiation before their operation, erasing more hidden cancer cells upfront, then complete one year of maintenance immunotherapy to guard against recurrence. The goal is simple: more patients stay cancer-free longer, live fuller lives, and avoid the heartbreak of cancer relapse. Conclusion: Immunotherapy and Total Neoadjuvant Therapy Bring Fresh Hope to Esophageal Cancer Care<br>Esophageal squamous cell carcinoma remains one of humanity\u2019s most devastating cancer threats, carrying staggering diagnosis and death rates concentrated heavily across China and East Asia. For decades, standard neoadjuvant chemoradiotherapy followed by surgery represented the best curative option for locally advanced resectable disease, yet nearly half of all patients suffered cancer recurrence after treatment. The split between pre-operative and post-operative systemic therapy created a critical flaw: too many patients could not finish life-saving adjuvant chemo after the physical strain of esophageal surgery.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Total neoadjuvant therapy (TNT) solves this core limitation by delivering all systemic chemotherapy and immunotherapy before surgery, while adebrelimab unlocks the patient\u2019s own immune system to hunt down hidden microscopic cancer cells that radiation and chemo alone might miss. The trial led by Dr. Yin Li\u2019s team at the National Cancer Center Beijing takes a two-stage approach to refine and validate this new treatment paradigm: Phase 2 compares two different TNT treatment sequences to identify the most effective, tolerable order, and Phase 3 confirms whether the winning regimen outperforms global standard chemoradiotherapy for long-term survival.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This research is more than a clinical study\u2014it is a beacon of hope for thousands of esophageal cancer patients and their caregivers. It seeks to raise cure rates, extend cancer-free survival time, and reduce the heartache of tumor recurrence through smarter, fully pre-operative combination therapy pairing radiation, chemotherapy, and cutting-edge domestic immunotherapy. As the trial moves forward through its enrollment, treatment, and multi-year follow-up phases, the global oncology community waits eagerly for results that could rewrite the rulebook for how we treat locally advanced esophageal squamous cell carcinoma for generations to come.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For patients interested in learning more about participation, the trial\u2019s central contact is Chief Physician Jianjun Qin at the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing, reachable via phone (+86-13838008630) or email (qinjianjun@cicams.ac.cn). All inquiries about trial eligibility, location, and participation logistics are welcome for qualified patients meeting the published inclusion criteria.<\/p>\n\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=37694\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n\n<hr class=\"wp-block-separator\"\/>\n\n<h2>Related Clinical Trials<\/h2>\n\n<h4>A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer<\/h4>\n<p>The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Esophageal Cancer<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=22369\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction<\/h4>\n<p>Both neoadjuvant chemoradiotherapy (CROSS) and neoadjuvant chemotherapy (FLOT) have demonstrated overall survival benefit over surgery alone in esophageal and esophagogastric junction (EGJ) cancer. Despite these survival gains, the prognosis remains poor, especially in patients with nodal-positive adenocarcinoma (cN+ AC) (5-year survival 36%, compared to 55% for cN0). This highlights the need for more effective treatment options, and justifies treatment intensification in these patients. The aim of this study is to determine the efficacy and feasibility of TNT FLOT-CROSS and TNT CROSS-FLOT in patients with resectable, cN+ AC of the esophagus or EGJ.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=14771\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)\/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)<\/h4>\n<p>This is a Phase 1\/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and\/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1\/PD-L1 based treatment.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=3060\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC<\/h4>\n<p>Concurrent chemoradiotherapy is now considered to be the standard treatment modality for esophageal cancer patients who are medically unfit for surgery. However, elderly patients have limitations in their ability to tolerate concurrent chemoradiotherapy in comparison to nonelderly patients because of medical comorbidities and reduced functional reserve of organs. Immune checkpoint inhibitors, including PD-1 inhibitor, have been used in a large number of clinical studies on esophageal cancer and have achieved certain results. PD-1 inhibitor combined with radiotherapy may be a new strategy for elderly patients with esophageal cancer. This study aims to explore the efficacy and safety of PD-1 inhibitor combined with radiotherapy in the treatment of elderly patients with esophageal cancer. PD-1 inhibitor was delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=15242\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma<\/h4>\n<p>Effective systemic therapy such as nivolumab as an adjuvant therapy has been demonstrated to improve the outcomes of patients receiving neoadjuvant chemoradiotherapy (CRT) for locoregional esophageal cancer. A more effective systemic therapy with anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) plus cisplatin-based doublet chemotherapy, which has shown with high tumor response rate and improved survivals in patients with late-stage ESCC, may provide crucial benefit to patients with locally advanced disease by improving the systemic control, downstaging the locoregional tumor burden and reducing recurrence and metastasis. Collectively, the investigators hypothesize that total neoadjuvant therapy (TNT) approach-consisting of induction immunochemotherapy followed by CRT-is a promising strategy to enhance the outcomes for participants with locally advanced esophageal squamous cell carcinoma.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=33722\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer<\/h4>\n<p>The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery: 1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery. 2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=12152\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 \/ BIORESOURCE)<\/h4>\n<p>Cancer of the stomach and oesophagus is among the world&#x27;s top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut. The proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=3889\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Exercise Training After Upper Gastrointestinal Cancer Surgery<\/h4>\n<p>This randomized controlled trial aims to determine the optimal exercise intensity for improving postoperative recovery in patients with upper gastrointestinal cancer. Participants who have undergone curative surgery will be randomly assigned to high-intensity interval training (HIIT), low-intensity continuous training (LICT), or usual care. The exercise interventions will be performed under supervision three times per week for eight weeks. The primary outcome is peak oxygen uptake (VO\u2082peak), assessed using cardiopulmonary exercise testing. Secondary outcomes include physical function, body composition, patient-reported outcomes, and biological and mechanistic markers such as inflammatory biomarkers, muscle-related factors, and gut microbiota. This study will also explore potential mechanisms underlying exercise-induced adaptations and their association with clinical outcomes.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=69027\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment<\/h4>\n<p>This is an open-label,multi-centre, phase 1b safety and feasibility study aiming to assess the safey and feasibility of bemarituzumab plus chemiotherapy (FLOT) for the peri-operative treatment of resectable gastroesophageal cancer. Following this neo-adjuvant part, patients should undergo surgery. Following surgery, patients will receive FLOT chemotherapy in combination with bemarituzumab. Imaging will be performed every 3 months for the first 2 years and thereafter every 6 months as per standard of care.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=42521\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer<\/h4>\n<p>To evaluate the feasibility, applicability, effectiveness, and health-economic value of the risk-based sequential screening modality for esophageal and gastric cancers, the investigators aim to initiate a community-based randomized controlled trial in Xun County, Henan Province, which is a high-risk region of upper gastrointestinal cancer (UGIC) in northern China. A total of 258 target villages from all the 11 communities (townships and streets) in Xun County will be randomly selected and assigned to the sequential screening group and the universal screening group at a ratio of 2:1 and the total sample size will be 21,000. In the sequential screening group, participants in the top 50% risk level (i.e., stratified as the high-risk subgroup) will be offered a standard upper gastrointestinal endoscopic screening. In contrast, all participants in the universal screening group will receive the endoscopic examination. The surveillance strategy for participants with screening-detected premalignant lesions in the sequential screening group will be tailored based on individualized risk assessment using endoscopic characteristics, pathological diagnosis, and biomarkers. Surveillance for participants in the universal screening group will adhere to current guidelines for UGIC screening and clinical treatment. Detection rates of upper gastrointestinal malignant lesions, early-stage malignant lesions and premalignant lesions, and health-economic indicators such as the unit cost per detected malignant lesions will be compared between the two groups.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=17869\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Predicting Esophageal Cancer Borders Using PET-Imaging<\/h4>\n<p>The study examines the diagnostic precision of endosonography, mpMRI and PET\/CT in defining tumor boundaries and tumor spread before and after neoadjuvant therapy and definitive surgery.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=20289\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)<\/h4>\n<p>The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal carcinoma.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=3426\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial<\/h4>\n<p>Cancer of the food pipe (oesophagus) and stomach are increasingly common. Currently, most patients with cancer of the oesophagus and stomach are treated with surgery with or without additional chemotherapy or radiotherapy. In recent years there have been improvements in survival from these two cancers, due to better therapies, less invasive surgery and earlier detection. Despite these improvements, in around half of patients treated with surgery, the cancer will return, usually within the first three years. At present there is very little evidence as to how patients who have been treated for cancer of the oesophagus or stomach should be followed up after surgery and whether different methods of follow-up could improve survival. Currently, national and international guidelines do not provide consistency in their recommendations for follow-up after surgery. The SARONG-II study will investigate if regular radiological scans can lead to earlier detection of a cancer returning, at a stage when it may be more readily treatable. This means that participants who agree to take part will be allocated by chance to either more intensive imaging surveillance (including regular radiological scans and a camera test (endoscopy)) or clinical follow-up. The study aims to recruit at least 952 participants in Europe over a 32-month period. Patients undergoing surgery for oesophageal or stomach cancer will be invited to participate in the study at around 4 to 8 weeks after their surgery. (i) The imaging surveillance group will receive a review in clinic or by telephone with a member of the surgical team, and a radiological scan at 6, 12, 18, 24, 30 and 36 months after randomisation. They will also receive endoscopy at 12 months after randomisation (ii) The clinical surveillance group will receive a review in clinic or by telephone at 6, 12, 18, 24, 30 and 36 months. After this they will be either discharged to their local doctor or receive a review in clinic with a member of the surgical team every year according to local practice The main aim of this study will be to determine whether earlier detection of cancer through more intensive follow-up results in improved survival and better quality of life for patients with oesophagus or stomach cancer. The investigators anticipate the results of the study may have significant practice-changing impact for patients undergoing follow-up after surgery for oesophagus and stomach cancer.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=13880\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Oncolytic Virus in Esophageal Squamous Cell Carcinoma<\/h4>\n<p>This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced esophageal squamous cell carcinoma (ESCC). The primary endpoints are safety, surgical conversion rate and event-free survival (EFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), and quality of life (QoL). Exploratory endpoints include biomarker analyses such as single-cell sequencing.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=46153\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma<\/h4>\n<p>The goal of this clinical trial is to learn if adding high-dose-rate (HDR) brachytherapy can improve outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who have already received external beam radiotherapy (EBRT), chemotherapy, and the immune therapy drug nivolumab. The main questions it aims to answer are: * Does HDR brachytherapy reduce the chance of the cancer coming back in the esophagus or nearby areas within 12 months? * What side effects or safety issues occur when HDR brachytherapy is given after EBRT, chemotherapy, and nivolumab? Participants will: * Receive 1-2 sessions of HDR brachytherapy delivered through a thin tube placed inside the esophagus, within three weeks after starting nivolumab. * Continue nivolumab and be monitored with regular follow-up visits, imaging tests, and blood samples to check treatment response and safety.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=50188\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D\/Keymaker-U06)<\/h4>\n<p>This is a phase 1\/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=21296\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E\/KEYMAKER-U06)<\/h4>\n<p>Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts. Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=34359\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy<\/h4>\n<p>This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer. The study primarily includes patients with esophageal cancer who underwent neoadjuvant chemoradiotherapy and surgery and did not achieve complete pathological response (non-pCR) postoperatively and were defined as preoperative clinical stage at T3-4N+M0. Eligible patients will be randomized in a 1:1 ratio into two groups: the observation group and the adjuvant radiotherapy group. The control group consists of patients who receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by maintenance therapy with PD1\/PDL1 inhibitors for up to 1 year or until tumor progression. The adjuvant radiotherapy group receives additional adjuvant radiotherapy on top of the control group&#x27;s treatment. The specific treatment process involves receiving 2 cycles of neoadjuvant chemotherapy combined with immunotherapy (PD1\/PDL1 inhibitors) before potentially curative esophageal cancer surgery. The chemotherapy regimen includes paclitaxel in combination with platinum agents, with a preference for albumin-bound paclitaxel (280mg\/m2 on Day 1, or 100mg on Days 1, 8, and 15) in combination with carboplatin (AUC=5). Following surgery, patients start adjuvant radiotherapy 4-6 weeks after the operation, with a radiation dose of 45Gy\/25F\/5W, completed no later than 8 weeks post-surgery. Two weeks after completing radiotherapy, patients continue with immunotherapy maintenance therapy for up to 1 year or until tumor progression. Subsequently, follow-up visits are scheduled every 3-4 months for the first 3 years, every 6 months for the next 2 years, and annually thereafter. The primary endpoint is 2-year disease-free survival (DFS), and secondary endpoints include overall survival (OS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), recurrence patterns, and safety assessment. Additionally, the study will explore biomarkers predicting treatment efficacy and adverse reactions in subjects, including PD-L1 expression, ctDNA clearance status, infiltrating immune cell types and quantities, cytokine expression, and other tumor biomarkers. This exploration aims to guide stratified precision treatment for patients.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=17072\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Paclitaxel and Ramucirumab +\/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma<\/h4>\n<p>This study is being done to answer the following question: Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=12422\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<h4>Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)<\/h4>\n<p>Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities. Previous trials have demonstrated that CRT with oral S-1 was tolerable and provided significant survival benefits over radiotherapy alone in elderly patients with esophageal squamous cell carcinoma (ESCC). However, as high as 54% of patients with elderly ESCC experienced locoregional or distant recurrence after CRT. Therefore, a more effective regimen for older patients is needed. Immune checkpoint inhibitors targeting PD-1\/PD-L1 have shown substantial clinical benefits in advanced esophageal cancer. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in locally advanced esophageal cancer. The aim of this study was to evaluate the efficacy and safety of toripalimab (an anti-PD-1 antibody) after concurrent CRT in elderly patients with locally advanced ESCC.<\/p>\n<a href=\"https:\/\/trialcontact.com\/?add-to-cart=15263\" class=\"button\" style=\"display:inline-block; padding:8px 22px; background:#0077bb; color:#fff; text-decoration:none; border-radius:5px; font-weight:500; font-size:15px; box-shadow:0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2); transition:all 0.1s ease;\" onmouseover=\"this.style.boxShadow='0 2px 0 #004470, 0 4px 6px rgba(0,0,0,0.18)'; this.style.transform='translateY(3px)'\" onmouseout=\"this.style.boxShadow='0 5px 0 #004470, 0 7px 12px rgba(0,0,0,0.2)'; this.style.transform='translateY(0)'\">\n        <span style=\"display:inline-block; background:#fff; color:#d62828; font-weight:bold; font-size:12px; padding:2px 5px; border-radius:3px; margin-right:8px;\">PDF<\/span>$29 only! Buy Clinical Trial Full Report With Contact Info\n    <\/a><br><br>\n<br>\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>If you or someone you love has faced an esophageal cancer diagnosis, you know how overwhelming the news can be. Esophageal cancer ranks among the<a href=\"https:\/\/trialcontact.com\/?p=72927\" class=\"more-link\"><span class=\"screen-reader-text\"> &#8220;Advanced Esophageal Squamous Cell Carcinoma: Combining Adebrelimab Immunotherapy and Total Neoadjuvant Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-72927","post","type-post","status-publish","format-standard","hentry","category-esophagealcancer"],"_links":{"self":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts\/72927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72927"}],"version-history":[{"count":3,"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts\/72927\/revisions"}],"predecessor-version":[{"id":72930,"href":"https:\/\/trialcontact.com\/index.php?rest_route=\/wp\/v2\/posts\/72927\/revisions\/72930"}],"wp:attachment":[{"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trialcontact.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}